[1] |
Tohyama M, Hashimoto K. Immunological mechanisms of epidermal damage in toxic epidermal necrolysis[J]. Curr Opin Allergy Clin Immunol, 2012, 12(4): 376⁃382. DOI: 10.1097/ACI. 0b013e328355b865.
|
[2] |
Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis[J]. Arch Dermatol, 1994, 130(5): 605⁃608. DOI: 10.1001/archderm. 1994.01690050073012.
|
[3] |
Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis[J]. J Invest Dermatol, 2004, 123(5): 850⁃855. DOI: 10.1111/j.0022⁃202X.2004.23439.x.
|
[4] |
丁兰, 路丹丹, 施辛, 等. 肿瘤坏死因子拮抗剂治疗重症三氯乙烯药疹样皮炎[J]. 中华皮肤科杂志, 2014, 47(4): 243⁃246. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.04.004.
|
|
Ding L, Lu DD, Shi X, et al. A tumor necrosis factor antagonist in the treatment of severe medicamentosa⁃like dermatitis induced by trichloroethylene: a clinical observation[J]. Chin J Dermatol, 2014, 47(4): 243⁃246. DOI: 10.3760/cma.j.issn.0412⁃4030.2014. 04.004.
|
[5] |
Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti⁃TNF⁃alpha treatment[J]. J Allergy Clin Immunol, 2005, 116(4): 923⁃924. DOI: 10.1016/j.jaci.2005.06.029.
|
[6] |
Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factor⁃alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis[J]. Br J Dermatol, 2002, 146(4): 707⁃709. DOI: 10.1046/j.1365⁃2133.2002.46833.x.
|
[7] |
陈玲玲, 路丹丹, 施辛, 等. 肿瘤坏死因子α拮抗剂治疗一例伴嗜酸性粒细胞增多和系统症状药疹的临床观察[J]. 中华皮肤科杂志, 2013, 46(9): 621⁃625. DOI: 10.3760/cma.j.issn.0412⁃4030.2013.09.003.
|
|
Chen LL, Lu DD, Shi X, et al. Drug rash with eosinophilia and systemic symptoms controlled by tumor necrosis factor⁃α antagonist: a clinical observation[J]. Chin J Dermatol, 2013, 46(9): 621⁃625. DOI: 10.3760/cma.j.issn.0412⁃4030.2013.09.003.
|
[8] |
Sadighha A. Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: definition of a new model based on translational research[J]. Int J Dermatol, 2009, 48(8): 913⁃914. DOI: 10.1111/j.1365⁃4632. 2008.04020.x.
|
[9] |
Prins C, Vittorio C, Padilla RS, et al. Effect of high⁃dose intra⁃venous immunoglobulin therapy in Stevens⁃Johnson syndrome: a retrospective, multicenter study[J]. Dermatology, 2003, 207(1): 96⁃99. DOI: 10.1159/000070957.
|
[10] |
Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas⁃L to be related to disease severity[J]. J Allergy Clin Immunol, 2002, 109(1): 155⁃161. DOI: 10.1067/mai.2002.120563.
|
[11] |
Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis[J]. J Am Acad Dermatol, 2014, 71(2): 278⁃283. DOI: 10.1016/j.jaad.2014.04.044.
|